Varfarin kullanan hastada olanzapin tedavisinin INR üzerine etkisi

Olanzapin psikotik belirtilerin tedavisinde kullanılan, psikotik bozuklukların ve duygudurum bozukluklarının tedavisinde başarılı, etki gücü yüksek (potent) bir ikinci kuşak antipsikotiktir. Derin ven trombozu bir venöz tromboemboli kliniği olup, antipsikotik tedavi alan hastalarda tromboz riskinin arttığı bilinmektedir. Olanzapin tedavisinin venöztromboz üzerine olan etkileri raporlanmış olmasına rağmen, literatürde olanzapin tedavisinin “international normalized ratio” (INR) üzerine etkileri hakkında bir çalışma bulunmamaktadır. Bu olgu bildiriminde derin ven trombozu aile öyküsü olup, olanzapin tedavisi altında derin ven trombozu atağı geçiren ve antikoagülan tedavisi alan şizofreni tanılı bir hastada olanzapinin INR üzerine etkilerinin ele alınması amaçlanmıştır.

Anahtar Kelimeler:

Olanzapin, INR, tromboz

Effect of olanzapine treatment on INR of a patient receiving warfarin therapy

Olanzapine is an atypical antipsychotic drug, commonly used in the management of psychotic symptoms in patients with schizoprenia and bipolar affective disorder. Deep venous thrombosis is a manifestation of venous thromboembolism. It is very well known that use of antipsychotic drugs increase the risk of thrombosis in a patient with schizophrenia. It has been reported in many studies the effects of olanzapine on thrombosis but there isn’t any report about the effect of olanzapine on international normalized ratio (INR). in the medical literature. In this paper, a patient with schizophrenia and also family history of deep venous thrombosis who emerged deep venous thrombosis after being started on olanzapine treatment and effect of olanzapine treatment on INR has been reported.

PDF

___

Stahl SM. Stahl’ın Temel Psikofarmakolojisi 3. Baskı (Çev. IT Uzbay):327-450. İstanbul, İstanbul Tıp Kitapevi, 2012.
Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al. The long-term clinical course of acute deep venous thrombosis, Ann Intern Med.1996;125:1-7
Zornberg GL, Jick H. Antipsychotic drug use and risk thromboembolism: a case control study. Lancet. 2000;356:1219–23. idiopathic venous
Poller L. International normalized ratios (INR): the first 20 years. J Thromb Haemost. 2004;2:849-60.
Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165:2677–82.
Hagg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol. 2003;18:299–300.
Waage IM, Gedde-Dahl. A Pulmonary embolism possibly associated with olanzapine treatment. BMJ. 2003;327-84.
Morioka H, Nagatomo I, Yamada K, Horikiri Y, Okamura H, Takigawa M. Deep venous thrombosis of the leg due to psychiatric stupor. Psychiatry Clin Neurosci. 1997;51:323-6.
Borras L, Eytan A, De Timary P, Constant EL, Huguelet thromboembolism associated with olanzapine and risperidone. J EmergMed. 2008;35:159–61.
Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K et al. Incidence of deep vein thrombosis in restrained psychiatric patients. Psychosomatics. 2014;55:69-75.
Sangiorgio P, Sarlatto C. Physical restraint in general hospital psychiatric units in the metropolitan area of Rome. IJMH. 2008;37:3–17.
Koga M, Nakayama K. Body weight gain induced by a newer antipsychotic agent. Acta Psychiatr Scand. 2005;112:75–6.
Hummer M, Huber J. Hyperprolactinemia and antipsychotic therapy in schizophrenia. Curr Med Res. 2004;20:189–97.
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;21:341:c4245.
Hamanaka S, KamijoY NT, Kurihara K, Tanaka K,
Soma K, Miyaoka H. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J. 2004;68:850–52.
Maempel JFZ, Darmanin G, Naeem K, Patel M. Olanzapine and pulmonary embolism, a rare association: a case report. Cases Journal. 2010;3:36.
Gill SS, Bronskill SE, Normand S-L, Anderson GM, Sykora K, Lam K et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-86.
Rochon PA, Normand S-L, Gomes T, Gill SS, Anderson GM, Melo Met al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168:1090-6.
Dickson BC, Pollanen MS. Fatal thromboembolic
disease: a risk in physically restrained psychiatric patients. J Forensic Leg Med. 2009;16:284–6.